Carolyn F. Deacon

Carolyn F. Deacon

Associate Professor


  1. 2007
  2. Published

    Dipeptidyl peptidase 4 inhibition with sitagliptin: a new therapy for type 2 diabetes.

    Deacon, Carolyn F., 2007, In: Expert Opinion on Investigational Drugs. 16, 4, p. 533-45 12 p.

    Research output: Contribution to journalJournal articlepeer-review

  3. Published

    Exendin-4, but not dipeptidyl peptidase IV inhibition, increases small intestinal mass in GK rats.

    Simonsen, L., Pilgaard, S., Orskov, C., Rosenkilde, Mette, Hartmann, B., Holst, Jens Juul & Deacon, Carolyn F., 2007, In: American Journal of Physiology: Gastrointestinal and Liver Physiology. 293, 1, p. G288-95

    Research output: Contribution to journalJournal articlepeer-review

  4. Published

    Incretin-based treatment of type 2 diabetes: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors.

    Deacon, Carolyn F., 2007, In: Diabetes, Obesity and Metabolism. 9 Suppl 1, p. 23-31 8 p.

    Research output: Contribution to journalJournal articlepeer-review

  5. Published

    Measurements of islet function and glucose metabolism with the dipeptidyl peptidase 4 inhibitor vildagliptin in patients with type 2 diabetes

    Azuma, K., Rádiková, Z., Mancino, J., Toledo, F. G. S., Thomas, E., Kangani, C., Dalla Man, C., Cobelli, C., Holst, Jens Juul, Deacon, Carolyn F., He, Y., Ligueros-Saylan, M., Serra, D., Foley, J. E. & Kelley, D. E., 2007, In: Journal of Clinical Endocrinology and Metabolism. 93, 2, p. 459-464 5 p.

    Research output: Contribution to journalJournal articlepeer-review

  6. Published

    New horizons in diabetes therapy

    Holst, Jens Juul & Deacon, Carolyn F., 2007, In: Immunology, Endocrine and Metabolic Agents in Medicinal Chemistry. 7, 1, p. 49-55 6 p.

    Research output: Contribution to journalJournal articlepeer-review

  7. Published

    Pharmacodynamics of vildagliptin in patients with type 2 diabetes during OGTT.

    He, Y., Wang, Y., Bullock, J. M., Deacon, Carolyn F., Holst, Jens Juul, Dunning, B. E., Ligueros-Saylan, M. & Foley, J. E., 2007, In: Journal of Clinical Pharmacology. 47, 5, p. 633-41 8 p.

    Research output: Contribution to journalJournal articlepeer-review

  8. Published

    Pharmacokinetics and pharmacodynamics of vildagliptin in patients with type 2 diabetes mellitus.

    He, Y., Serra, D., Wang, Y., Campestrini, J., Riviere, G., Deacon, Carolyn F., Holst, Jens Juul, Schwartz, S., Nielsen, J. C. & Ligueros-Saylan, M., 2007, In: Clinical Pharmacokinetics. 46, 7, p. 577-88 11 p.

    Research output: Contribution to journalJournal articlepeer-review

  9. Published

    Suppression of glucagon secretion is lower after oral glucose administration than during intravenous glucose administration in human subjects

    Meier, J. J., Deacon, Carolyn F., Schmidt, W. E., Holst, Jens Juul & Nauck, M. A., 2007, In: Diabetologia. 50, 4, p. 806-813 7 p.

    Research output: Contribution to journalJournal articlepeer-review

  10. Published

    The dipeptidyl peptidase IV inhibitor vildagliptin suppresses endogenous glucose production and enhances islet function after single-dose administration in type 2 diabetic patients.

    Balas, B., Baig, M. R., Watson, C., Dunning, B. E., Ligueros-Saylan, M., Wang, Y., He, Y., Darland, C., Holst, Jens Juul, Deacon, Carolyn F., Cusi, K., Mari, A., Foley, J. E. & DeFronzo, R. A., 2007, In: Journal of Clinical Endocrinology and Metabolism. 92, 4, p. 1249-55 6 p.

    Research output: Contribution to journalJournal articlepeer-review

  11. Published

    The dipeptidyl peptidase-4 inhibitor vildagliptin improves beta-cell function and insulin sensitivity in subjects with impaired fasting glucose

    Utzschneider, K. M., Tong, J., Montgomery, B., Udayasankar, J., Gerchman, F., Marcovina, S. M., Watson, C. E., Ligueros-Saylan, M. A., Foley, J. E., Holst, Jens Juul, Deacon, Carolyn F. & Kahn, S. E., 2007, In: Diabetes Care. 31, 1, p. 108-113 5 p.

    Research output: Contribution to journalJournal articlepeer-review

ID: 9220